Daclizumab: Novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation

被引：15

作者：

Vincenti, F ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Clin Med, San Francisco, CA 94143 USA

来源：

TRANSPLANTATION PROCEEDINGS | 1999年 / 31卷 / 06期

关键词：

D O I：

10.1016/S0041-1345(99)00307-3

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：2206 / 2207

页数：2

共 6 条

[1] Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients [J].

Nashan, B ;

Moore, R ;

Amlot, P ;

Schmidt, AG ;

Abeywickrama, K ;

Soulillou, JP .

LANCET, 1997, 350 (9086) :1193-1198

[2]

NASHAN B, IN PRESS TRANSPLANTA

[3]

TANIGUCHI T, 1993, CELL, V75, P5

[4] A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation [J].

Vincenti, F ;

Lantz, M ;

Birnbaum, J ;

Garovoy, M ;

Mould, D ;

Hakimi, J ;

Nieforth, K ;

Light, S .

TRANSPLANTATION, 1997, 63 (01) :33-38

[5] Daclizumab: Outcome of phase III trials and mechanism of action [J].

Vincenti, F ;

Nashan, B ;

Light, S .

TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) :2155-2158

[6] Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation [J].

Vincenti, F ;

Kirkman, R ;

Light, S ;

Bumgardner, G ;

Pescovitz, M ;

Halloran, P ;

Neylan, J ;

Wilkinson, A ;

Ekberg, H ;

Gaston, R ;

Backman, L ;

Burdick, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (03) :161-165

← 1 →